Instem has acquired Samarind, a UK-based supplier of Regulatory Information Management solutions to the global life sciences industry. It is paying up to £2.5m largely from existing cash resources and we expect the deal to be materially earnings enhancing. We upgrade our FY16 EPS forecasts by 5% and by 14% in FY17. The acquisition looks a good fit with Instem’s existing regulatory submission expertise and broadens the offering into post-marketing regulatory affairs services. The shares look good ....
